These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37478179)

  • 21. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay.
    Smith SJ; Ferris A; Zhao X; Pauly G; Schneider JP; Burke TR; Hughes SH
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
    Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
    Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
    J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.
    Smith SJ; Zhao XZ; Burke TR; Hughes SH
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
    Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
    PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.
    Henegar C; Letang E; Wang R; Hicks C; Fox D; Jones B; de Ruiter A; Vannappagari V
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.
    Zhao XZ; Smith SJ; Maskell DP; Métifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR
    J Med Chem; 2017 Sep; 60(17):7315-7332. PubMed ID: 28737946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.
    Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33572956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.
    Richetta C; Tu NQ; Delelis O
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir.
    Cutillas V; Mesplede T; Anstett K; Hassounah S; Wainberg MA
    Antimicrob Agents Chemother; 2015 Jan; 59(1):310-6. PubMed ID: 25348535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity.
    Anstett K; Brenner B; Mesplède T; Wainberg MA
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV drug resistance against strand transfer integrase inhibitors.
    Anstett K; Brenner B; Mesplede T; Wainberg MA
    Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
    DeAnda F; Hightower KE; Nolte RT; Hattori K; Yoshinaga T; Kawasuji T; Underwood MR
    PLoS One; 2013; 8(10):e77448. PubMed ID: 24146996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis of second-generation HIV integrase inhibitor action and viral resistance.
    Cook NJ; Li W; Berta D; Badaoui M; Ballandras-Colas A; Nans A; Kotecha A; Rosta E; Engelman AN; Cherepanov P
    Science; 2020 Feb; 367(6479):806-810. PubMed ID: 32001525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.